Responses
Regular and Young Investigator Award Abstracts
Cellular Therapies
348 TIL engineered with membrane-bound IL15 (cytoTIL15™) are enriched for tumor-associated antigen reactivity and demonstrate pharmacologically tunable expansion and persistence in the presence of TAA
Compose a Response to This Article
Other responses
No responses have been published for this article.
